"Designing Growth Strategies is in our DNA"

U.S. Opioid Use Disorder (OUD) Market Size, Share & Industry Analysis, By Drug Class (Buprenorphine, Methadone, and Naltrexone), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Stores, and Online Pharmacies), and Country Forecast, 2024-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI108778

 

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trend
  4. Key Insights
    1. Pipeline Analysis-Key Products
    2. New Product Launches
    3. Statistics of Opioid Use Disorder in the U.S.
    4. Industry Developments Such as Mergers, Acquisitions, and Collaborations
    5. Impact of COVID-19 on Opioid Use Disorder (OUD) Market
  5. U.S. Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Type
      1. Buprenorphine
      2. Methadone
      3. Naltrexone
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Stores
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2023)
    2. Company Profiles
      1. Indivior PLC
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Alkermes
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Orexo AB
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Titan Pharmaceuticals, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Hikma Pharmaceuticals PLC
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. BioDelivery Sciences International Inc
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Viatris Inc. (Mylan N.V.)
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Braeburn Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Camurus
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      10. Lannett
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
    4. Market Trend
  4. Key Insights
    1. Pipeline Analysis-Key Products
    2. New Product Launches
    3. Statistics of Opioid Use Disorder in the U.S.
    4. Industry Developments Such as Mergers, Acquisitions, and Collaborations
    5. Impact of COVID-19 on Opioid Use Disorder (OUD) Market
  5. U.S. Opioid Use Disorder (OUD) Market Analysis, Insights and Forecast, 2019-2032
    1. Market Analysis, Insights and Forecast – By Drug Type
      1. Buprenorphine
      2. Methadone
      3. Naltrexone
    2. Market Analysis, Insights and Forecast – By Route of Administration
      1. Oral
      2. Parenteral
    3. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies & Stores
      3. Online Pharmacies
  6. Competitive Analysis
    1. U.S. Market Share Analysis (2023)
    2. Company Profiles
      1. Indivior PLC
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      2. Alkermes
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      3. Orexo AB
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      4. Titan Pharmaceuticals, Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      5. Hikma Pharmaceuticals PLC
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      6. BioDelivery Sciences International Inc
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      7. Viatris Inc. (Mylan N.V.)
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      8. Braeburn Inc.
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      9. Camurus
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
      10. Lannett
        1. Overview
        2. Product
        3. SWOT Analysis
        4. Recent Developments
        5. Strategies
        6. Financials (Based on Availability)
Read Less

Figure 1: U.S. Opioid Use Disorder (OUD) Market Revenue Breakdown (USD billion,%) by Drug Class, 2023 & 2032

Figure 2: U.S. Opioid Use Disorder (OUD) Market Value Share (%), by Drug Class, 2023 & 2032

Figure 3: U.S. Opioid Use Disorder (OUD) Market Value Share (%), by Route of Administration, 2023 & 2032

Figure 4: U.S. Opioid Use Disorder (OUD) Market Value Share (%), by Distribution Channel, 2023 & 2032

Figure 5: U.S. Opioid Use Disorder (OUD) Market Share (%), By Company, 2023

Table 1: U.S. Opioid Use Disorder (OUD) Market Revenue (USD Billion) Forecast, by Drug Class, 2019-2032

Table 2: U.S. Opioid Use Disorder (OUD) Market Revenue (USD Billion) Forecast, by Route of Administration, 2019-2032

Table 3: U.S. Opioid Use Disorder (OUD) Market Revenue (USD Billion) Forecast, by Distribution Channel, 2019-2032

U.S. Opioid Use Disorder (OUD) Market
  • 2019-2032
  • 2023
  • 2019-2022
  • 80
Download Free Sample

    man icon
    Mail icon
    Captcha refresh
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann

Related Reports